Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 7/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3932194 | 1.00 | DPP4 (0.47) | DPP4S1PR1S1PR5TACR1GAA | |
| SCHEMBL1721376 | 0.81 | S1PR1 (0.37) | S1PR1S1PR5FUCA1CHRM2CHRM3 | |
| SCHEMBL3926744 | 0.81 | S1PR1 (0.37) | S1PR1S1PR5FUCA1CHRM2CHRM3 | |
| SCHEMBL3926747 | 0.81 | S1PR1 (0.37) | S1PR1S1PR5FUCA1CHRM2CHRM3 | |
| SCHEMBL150105 | 0.79 | L3MBTL1 (0.47) | DPP4S1PR1S1PR5TACR1FUCA1 | |
| SCHEMBL3919422 | 0.78 | DRD2 (0.37) | — | |
| SCHEMBL148558 | 0.75 | KMT2A (0.42) | — | |
| SCHEMBL148557 | 0.75 | KMT2A (0.42) | — | |
| SCHEMBL31599630 | 0.71 | L3MBTL1 (0.51) | TACR1GAA | |
| SCHEMBL19327458 | 0.70 | FUCA1 (0.60) | DPP4S1PR1S1PR5FUCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485641-B2 | Substituted 3-amino-pyrrolidino-4-lactams | PFIZER, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| WO-2007148185-A2 | SUBSTITUTED 3 -AMINO- PYRROLIDINO-4 -LACTAMS AS DPP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2007-12-27 | — | — | WO | disclosed |
| US-20070299076-A1 | Substituted 3-Amino-Pyrrolidino-4-Lactams | PFIZER INC | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299076-A1 | Substituted 3-Amino-Pyrrolidino-4-Lactams | PRMT1, PRMT7, PRMT3 | DPP4 783/4885S1PR1 2333/4885S1PR5 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.